Deniz Tural, MD, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey, discusses the association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial cancer (mUC) at ASCO GU 2021. The results from this retrospective analysis of 105 patients suggest that clinical benefit from first-line chemotherapy was an independent prognostic factor of overall survival in patients with urothelial cancer receiving second-line treatment with atezolizumab. This interview took place during the 2021 Genitourinary Cancers Symposium.